CXCR4 and Hepatic fibrosis: We hypothesized that the CXCR4 antagonizing polymer used in this DDS, can efficiently deliver therapeutic anti-miR155 to KC and inhibit CXCR4 on HSC in parallel and reverse liver fibrosis.